@FiercePharma: What's a $2.9B deal + increasing sales equal? One enthused new CEO at Forest. Yesterday's story | Follow @FiercePharma
@TracyStaton: Here's my story on yesterday's Swiss job shuffle. Story | Follow @TracyStaton
@EricPFierce: Who do you think are the most influential people in biopharma? Like to see someone from manufacturing. Survey | Follow @EricPFierce
@CarlyHFierce: Vivus has lost more than half its board, its CFO, 2 CEOs and 20 staffers--and now its commercial chief, apparently. More | Follow @CarlyHFierce
> AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) won EU approval for Xigduo as a treatment for Type 2 diabetes. Release
> Without its pharma division AbbVie ($ABBV), spun off last January, Abbott Laboratories ($ABT) posted a 44% decline in annual profits. Report (sub. req.)
> Alexion Pharmaceuticals ($ALXN) won another orphan drug designation for Soliris, its pricey treatment already approved for two rare diseases. Release | Report
> Still fighting to block Hanmi's rival to its blockbuster stomach drug Nexium, AstraZeneca ($AZN) asked for a full rehearing of their patent fight in U.S. Circuit Court. Report (reg. req.)
> Bayer said its $2.9 billion offer for Norway's Algeta would be open till Feb. 24; the company rolled out a €2 billion ($2.7 billion) bond issue today, in part to finance the potential deal. Report | More
> Germany's Stada said its 2013 sales topped €2 billion ($2.7 billion), according to its preliminary figures. Report
> Pfizer ($PFE) sold its former animal health headquarters in Madison, NJ, to a group of private investors. Report
> The U.K.'s cost-effectiveness watchdogs approved transcranial magnetic stimulation as a treatment for migraine. Report
> Novartis ($NVS) launched a topical diclofenac gel, Voveran TPM, in India. Report
Biotech News
@FierceBiotech: The dethroned 'King of Biotech' will stay exiled in prison. News | Follow @FierceBiotech
@JohnCFierce: The 4th quarter was big--Q4 venture haul pushes 2013 biotech investing past $4.5B--and the year was fine, overall. Story | Follow @JohnCFierce
@DamianFierce: Your chance to vote: Who are the most influential people in biopharma today? Survey | Follow @DamianFierce
@EmilyMFierce: ICYMI, yesterday's edition of FierceBiotech Research featured Alzheimer's research and new nanotech. Read | Follow @EmilyMFierce
> Boehringer, Zealand hit reset on GLP-1 diabetes program. More
> U.K. mulls a 'breakthrough' drug program of its own. Article
> Yale researchers chide the FDA for failing to enforce high R&D standards. Coverage
@FierceMedDev: Special Report: 2013's top FDA approvals in med tech. Report | Follow @FierceMedDev
@MarkHFierce: Check out the latest issue of FierceDiagnostics, now with expanded biomarker coverage. Issue | Follow @MarkHFierce
@MichaelGFierce: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Covidien gets FDA OK for LigaSure laparoscopic surgical device. News | Follow @EmilyWFierce
> Diagnostics buoyed Abbott's Q4 numbers, but diabetes sales declined. Report
> Cohera Medical's surgical sealants attracted a $26.3M Series D. More
> St. Jude Medical reports solid growth, predicts more to come. News
Drug Delivery News
> Nano-scaffold delivers genetic treatment to spur blood vessel growth. News
> Biotronik launches drug-releasing balloon Passeo-18 Lux in Europe. Article
> NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story
> Rooted delivery vehicles use electric charge and gravity to release drugs over time. Piece
> Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story
> Novartis launches joint pain gel in India with Phosphagenics' delivery tech. Item
Diagnostics News
> Researchers from Singapore and China find a new esophageal cancer biomarker. More
> A finger-prick blood test could uncover sports concussions on the field. Article
> Myriad Genetics will market a breast cancer Dx made by a Siemens spinoff. Story
> FDA approves Affymetrix's blood test for developmental disabilities. Coverage
> Illumina brings next-generation sequencing to Amgen companion Dx deal. News
> LabCorp CEO promises continued rollout of new genomics-based Dx tests. Item
And Finally... Yellowstone National Park decided not to vaccinate its roaming bison, the last purebred herd in the U.S., using so-called biobullets. Report